Breast Cancer (BC) is one of the most common malignant tumors. SR9009 Ethyl 3-[[(4-chlorophenyl) methyl-[(5-nitrothiophen-2-yl) methyl amino] methyl] pyrrolidine-1-carboxylate], a specific agonist of pyrrole derivatives has promising pharmaceutical agent and efficacy in treating several conditions including metabolic diseases such as obesity, bipolar, anxiety, depressive disorder and cancer. The goal of this study was to clarify the biological mechanism of SR9009 and develop a prediction target for SR9009 against BC using network pharmacology. We report 16 overlapping targets among 21 targets of SR9009 and 17622 known targets of breast cancer. Resulting, molecular docking analysis shows that SR9009 have affinity binding features with these hub gene targets for further consideration.
Stephen Ilango* (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: